問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Infectious Disease

Division of Thoracic Medicine

更新時間：2023-09-19

胡漢忠
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

胡漢忠

List

26Cases

2007-10-01 - 2008-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-11-01 - 2030-12-31

Phase II

Not yet recruiting
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    prefilled syringe

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-01-31 - 2028-01-30

Phase II

Active
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

  • Condition/Disease

    Asthma

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
7Sites

Recruiting7Sites

2025-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2027-11-30

Phase III

Active
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS

  • Condition/Disease

    COVID-19 SARS-CoV-2 Infection

  • Test Drug

    IBUZATRELVIR

Participate Sites
5Sites

Recruiting5Sites

2024-10-31 - 2026-12-31

Phase II

Active
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

  • Condition/Disease

    Asthma

  • Test Drug

    dry powder inhaler

Participate Sites
8Sites

Recruiting8Sites

2024-01-22 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Not yet recruiting7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Phase II

Active
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

  • Condition/Disease

    Bronchiectasis with chronic Pseudomonas aeruginosa infection

  • Test Drug

    Lyophilized powder for injection

Participate Sites
7Sites

Recruiting7Sites

2022-12-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-06-01 - 2028-12-31

Phase II

Active
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    Tablet

Participate Sites
10Sites

Recruiting10Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB